Timothy Walker

545 POSTS 0 COMMENTS
Tim is a contributing analyst for EconomicCalendar.com and specializes in equities trading and public offerings. He is a graduate of UCLA and began his career doing capital markets research for a top investment banking software provider.
laboratory

Calithera Biosciences (CALA) Hits Milestone with Incyte Corp (INCY) Partnership

Calithera Biosciences Inc (NASDAQ:CALA) announced this morning that it is entitled to receive a $12 million milestone payment from Incyte Corporation (NASDAQ:INCY) as per...
laboratory

Cara Therapeutics (CARA) Spikes on Encouraging Uremic Pruritus Data

Cara Therapeutics Inc (NASDAQ:CARA) is trading sharply higher today, following the company’s release of positive clinical data regarding its uremic pruritus (UP) product –...
laboratory

Wall Street is Positive on CytomX (CTMX) Extending Bristol-Myers Squibb (BMY) Deal

CytomX Therapeutics (NASDAQ:CTMX) is about two percent higher in early-afternoon trading today, a 36-cent boost to $18.15. This morning, it was announced that HC...
laboratory

Analyst Sees Major Catalyst for BioPharmX Corp (BPMX) in Coming Months

Earlier this morning, HC Wainwright announced that it was reaffirming a Buy rating on BioPharmX Corp (NYSE MKT:BPMX), and maintained a price target of...

Intec Pharma (NTEC) Begins Phase 1 Cannabinoid Clinical Trial

On Wednesday, Intec Pharma Ltd (NASDAQ:NTEC) announced that it had initiated a Phase 1 clinical program to evaluate its delivery system for marijuana-based therapeutics....
laboratory

Will Flexion Therapeutics (FLXN) be Snapped up by Sanofi (SNY)?

Flexion Therapeutics Inc (NASDAQ:FLXN) is surging today, with its shares currently $6.97 higher at $26.65 – a 35 percent jump. The boost arrived on...
laboratory

Analyst Sees Cytokinetics (CYTK) Stock Doubling in Value

Yesterday, Cytokinetics Inc (NASDAQ:CYTK) released preclinical data from its spinal muscular atrophy (SMA) drug, CK-107 – and the results were extremely encouraging. The company...
laboratory

Analysts on Standby for Phase 2/3 Data from Cara Therapeutics (CARA)

Cara Therapeutics Inc (NASDAQ:CARA) sunk 59 cents today – a 3.7 percent drop to $15.58 at the market close. Now seems like a wise...

Nektar Therapeutics’ (NKTR) Abuse-Deterrent Opioid Scores Phase 3 Win

Nektar Therapeutics Inc (NASDAQ:NKTR) skyrocketed 42 percent higher yesterday, finishing the regular trading session at $22.11 – a boost of $6.61.The surge came on...

Wedbush Sees Catabasis Pharmaceuticals (CATB) Nearly Tripling

Catabasis Pharmaceuticals Inc sunk more than six percent lower today, falling ten cents to hit $1.45 at the market close. Earlier this morning it...

Upcoming Economic Events

Other News

Is General Electric (GE) Stock A Solid Pick Following the Selloff?

General Electric (NYSE:GE) stock price declined nearly 5.5% in the last twelve months after touching 52-weeks high of $33 a share in the mid...
gold

Dollar Recovery Caps Gold Prices, Underlying Support Remains Firm

A rebound in the dollar and improved tone surrounding risk appetite has curbed support for gold, although the impact was offset by a fresh...
oil pipeline

Risk Recovery Boosts Crude Oil Prices, Markets Braced For Record Inventories

Oil prices have gained ground over the past 24 hours with a wider boost to risk appetite and disruptions to Libyan output underpinning prices...
crude oil

Halliburton (HAL) Stock Offers a Buying Opportunity

Halliburton (NYSE:HAL) share price started tumbling since peaking around $58 a share in the beginning of this year. HAL’s stock price declined nearly 11%...
silver price dollar coins

Silver Prices Stall as U.S. Dollar Recovery from Four-Month Low

Silver prices edged lower Wednesday, as demand for precious metals softened on improved risk sentiment and a rebounding U.S. dollar.May silver futures fell 9...
1,810FansLike
9,753FollowersFollow
1,185FollowersFollow